Gyre Therapeutics Files 8-K on Financials

Ticker: GYRE · Form: 8-K · Filed: Mar 17, 2025 · CIK: 1124105

Gyre Therapeutics, Inc. 8-K Filing Summary
FieldDetail
CompanyGyre Therapeutics, Inc. (GYRE)
Form Type8-K
Filed DateMar 17, 2025
Risk Levellow
Sentimentneutral

Sentiment: neutral

Topics: financial-reporting, sec-filing

TL;DR

GYRE filed an 8-K for financial results - check for details.

AI Summary

On March 17, 2025, Gyre Therapeutics, Inc. filed an 8-K report. The filing primarily concerns the company's results of operations and financial condition, as well as financial statements and exhibits. No specific financial figures or operational updates were detailed in the provided text.

Why It Matters

This filing indicates Gyre Therapeutics is providing updates on its financial status and operational results to the SEC, which is important for investors to monitor company performance.

Risk Assessment

Risk Level: low — The filing is a standard 8-K for financial reporting and does not contain any immediately alarming information.

Key Players & Entities

  • Gyre Therapeutics, Inc. (company) — Registrant
  • March 17, 2025 (date) — Date of earliest event reported
  • Delaware (jurisdiction) — State of incorporation
  • 12770 High Bluff Drive Suite 150 San Diego, CA 92130 (address) — Principal executive offices
  • ( 858 ) 567-7770 (phone_number) — Registrant's telephone number
  • CATALYST BIOSCIENCES, INC. (company) — Former company name
  • TARGACEPT INC (company) — Former company name

FAQ

What specific financial information is being reported in this 8-K?

The filing indicates it pertains to 'Results of Operations and Financial Condition' and 'Financial Statements and Exhibits', but the specific details are not provided in the text.

When was the earliest event reported in this filing?

The earliest event reported is dated March 17, 2025.

What is the principal executive office address for Gyre Therapeutics, Inc.?

The principal executive office is located at 12770 High Bluff Drive Suite 150 San Diego, CA 92130.

Has Gyre Therapeutics, Inc. operated under any former names?

Yes, Gyre Therapeutics, Inc. was formerly known as CATALYST BIOSCIENCES, INC. and TARGACEPT INC.

What is the SIC code for Gyre Therapeutics, Inc.?

The Standard Industrial Classification (SIC) code for Gyre Therapeutics, Inc. is 2834, which corresponds to Pharmaceutical Preparations.

Filing Details

This Form 8-K (Form 8-K) was filed with the SEC on March 17, 2025 regarding GYRE THERAPEUTICS, INC. (GYRE).

View full filing on EDGAR

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.